Dual-Action Dementia Composition for CYP2D6-Modulated NMDA Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for behavioral and psychological symptoms of dementia, such as Alzheimer's disease, vascular dementia, and Lewy Body dementia, are non-specific and often exacerbate symptoms, with a lack of disease-modifying therapies and significant adverse effects from existing pharmacological interventions.
Innovation Solution
A pharmaceutical composition comprising a dual agent that inhibits CYP2D6 and acts as a 5-HT2A receptor antagonist, combined with an NMDA receptor antagonist, such as dextromethorphan, to provide symptomatic relief and potential disease modification, administered in various forms and frequencies to optimize therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific pharmacological interventions are used to treat behavioral and psychological symptoms of dementia, then some symptomatic relief may be achieved, but adverse effects increase and symptoms are often exacerbated
Solution Approach 1:
The treatment approach is segmented into two distinct components: a CYP2D6 inhibitor to modulate metabolism and a 5-HT2A receptor antagonist to address behavioral symptoms. This segmentation allows each component to perform its specific function, reducing off-target effects while maintaining therapeutic efficacy.
Solution Approach 2:
The CYP2D6 inhibitor acts as an intermediary that modulates the metabolic pathway, controlling the activation and clearance of the 5-HT2A receptor antagonist. This intermediary mechanism ensures that the active compound is present at therapeutic levels only when needed, reducing adverse effects while maintaining reliability.
2Adaptability or versatility
If existing pharmacological treatments are administered to dementia patients, then some behavioral symptoms may be addressed, but the treatments are non-specific and lack disease-modifying capacity
Solution Approach 1:
The CYP2D6 inhibitor serves multiple functions: it modulates the metabolism of the 5-HT2A receptor antagonist, provides its own therapeutic effects through CYP2D6 inhibition, and enables disease-modifying potential by controlling the pharmacokinetic profile. This multi-functionality increases adaptability without proportionally increasing complexity.
Solution Approach 2:
The treatment utilizes parameter changes in the metabolic pathway by inhibiting CYP2D6 enzyme activity. This changes the pharmacokinetic parameters of the 5-HT2A receptor antagonist, extending its half-life and maintaining therapeutic levels longer, thereby adding disease-modifying potential to the treatment approach.
3Reliability
If CYP2D6 inhibitor and 5-HT2A receptor antagonist are combined in a pharmaceutical composition, then therapeutic efficacy is enhanced, but formulation complexity increases
Solution Approach 1:
The CYP2D6 inhibitor and 5-HT2A receptor antagonist are merged into a single pharmaceutical composition, ensuring coordinated delivery and maintaining the therapeutic ratio between the two components. This merging enhances reliability by ensuring both components are present simultaneously at appropriate concentrations, while the formulation complexity is managed through standardized manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves significant reduction in agitation and psychosis severity, improves cognitive and behavioral symptoms, and potentially modifies disease progression, while minimizing adverse effects through targeted receptor interaction and metabolic inhibition.
Implementation Method 1
a dual agent acting as a 5-HT2a receptor antagonist and CYP2d6 inhibitor
Implementation Method 2
acts as a 5-HT2a receptor antagonist
Implementation Method 3
an NMDA receptor antagonist
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3A~3C
AI summary
Compounds of formula I, (I) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N- oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: (IIa) (IIb) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.